Results of final exercise of warrants Y: additional €854K raised and extension of cash runway from May into July 2024
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
The term “biotherapies” broadly refers to medicinal products, including biopharmaceuticals, that are produced from biolo…
€1.48 million private placement secured from a group of new investors Buyback will mark the end of TME Pharma's converti…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Increasing geriatric population, growing preference for minimally invasive procedures like annuloplasty and transcathete…
Japanisches Ministerium für Gesundheit, Arbeit und Soziales erteilt Zulassung für Eylea 8 mg (MHLW) für neovaskuläre…
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX…
Neue Phase-II-Studie NIRVANA soll die Wirksamkeit und Sicherheit von Elinzanetant als nicht-hormonelle Behandlung von we…
Die zulassungsrelevanten Studien OASIS 1 und 2 erreichten alle primären Endpunkte und zeigten eine statistisch signifika…
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…